Clinical trials: Hepatitis C Virus (HCV)
Chronic Hepatitis C
Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection
The purpose of this study is to evaluate the antiviral efficacy, safety, tolerability of combination therapy with sofosbuvir (SOF) containing regimens for the treatment of chronic hepatitis C virus (HCV) infection.
- Trial name
- NCT01826981
- Testing
- LDV/SOF, SOF, RBV
- Where
- 2 sites in New Zealand
- Volunteers
- 359 people
- Sponsor
- Gilead Sciences
Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Background: The COVID-19 global pandemic killed more than 6 million people worldwide. Several vaccines have been developed against the virus that causes this disease.
- Conditions
- Chronic or Recovered Hepatitis B, Chronic or Recovered Hepatitis C, Chronic or Recovered Hepatitis D, NAFLD
- Trial name
- NCT05669677
- Where
- United States
- Volunteers
- 233 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C, Chronic
The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection
Primary Objective: To determine the P1101 pharmacokinetic (PK) profile at the single dose of 400 μg.
- Trial name
- NCT04774107
- Testing
- P1101 + Ribavirin
- Where
- 5 sites in Taiwan
- Volunteers
- 17 people
- Sponsor
- PharmaEssentia
Hepatitis C, Deglutition Disorders
Bioequivalence Study of Crushed Elbasvir/Grazoprevir Compared to the Whole Tablet
Elbasvir/grazoprevir (Zepatier®) is a once-daily tablet for the treatment of chronic hepatitis C virus (HCV) GT1a, 1b or 4 infection containing the NS5A inhibitor elbasvir (ELB) 50 mg and the NS3/4A protease inhibitor grazoprevir…
- Trial name
- CRUSADE-2 (NCT03817619)
- Testing
- Zepatier whole tablet, Zepatier crushed tablet
- Where
- Netherlands
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Hepatitis C
ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing
Hepatitis C virus (HCV) infection has become the leading fatal infectious disease in the United States. Approximately 75% of individuals who have been infected with HCV are chronically infected with the virus.
- Trial name
- NCT03767231
- Testing
- Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Chronic Hepatitis C
PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C
The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children.
- Trial name
- NCT00100659
- Testing
- Pegylated Interferon/ribavirin
- Where
- 11 sites in United States
- Volunteers
- 114 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C
Treatment Insulin Resistence in HCV G-1 Patient
To evaluate the effect of treatment of insulin resistance in the response of chronic hepatitis C treatment, mesure as HCV-RNA negative at week 72.
- Trial name
- TRIC-1 (NCT00546442)
- Testing
- Metformine
- Where
- 19 sites in Spain
- Volunteers
- 126 people
- Sponsor
- Valme University Hospital
Chronic Hepatitis C
Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)
The primary objective of this study is to determine the safe and effective dose range of boceprevir (SCH 503034) in combination with PEG-Intron in adult subjects who have chronic hepatitis C without cirrhosis, and who have failed…
- Trial name
- NCT00160251
- Testing
- Boceprevir (BOC), PegIntron (PEG), Ribavirin (RBV)
- Volunteers
- 357 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Infection
Therapeutic Hepatitis C Virus Vaccine
GC002 is a Phase I trial to evaluate the safety and the immune responses of a lentiviral based HCV immunotherapy (HCVax™) in chronic HCV patients.
- Trial name
- NCT04318379
- Testing
- HCVax
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- GeneCure Biotechnologies
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis
This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans with compensated cirrhosis and genotype 2 HCV…
- Trial name
- VALOR-HCV (NCT02128542)
- Testing
- Sofosbuvir, RBV
- Where
- 17 sites in United States
- Volunteers
- 66 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
This study will evaluate the effectiveness of an experimental treatment regimen for hepatitis C (HCV). Standard treatment consists of combination therapy with ribavirin, taken by mouth twice a day, and Peginterferon, injected…
- Trial name
- NCT00735969
- Testing
- Peginterferon, Ribavirin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C Infection
36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8
Purpose: To compare the effectiveness of 36 weeks versus 48 weeks pegintron plus ribavirin treatment for hepatitis C virus(HCV) patients without rapid virologic response(RVR), but with undetectable HCV RNA at wk 8.
- Trial name
- NCT01683786
- Testing
- Pegintron + Riba
- Where
- 5 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- Chang Gung Memorial Hospital
Chronic Hepatitis
Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
The study aimed at evaluating whether current 24 weeks length of combination treatment is appropriate or not for patients with HCV genotype 3 infection.
- Trial name
- genotype-3 (NCT01121705)
- Testing
- Peg Interferon alpha2b + Ribavirin
- Where
- 8 sites in Italy
- Volunteers
- 360 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Chronic Hepatitis C
Phase II Trial of Silymarin for Patients With Chronic Hepatitis C Who Have Failed Conventional Antiviral Treatment
Silymarin (Legalon), also known as milk thistle, is an alternative medicine commonly found in health food and vitamin stores. People with liver disease sometimes use silymarin because it is thought to have liver protecting…
- Trial name
- SyNCH (NCT00680342)
- Testing
- Silymarin
- Where
- 5 sites in United States
- Volunteers
- 154 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Hepatitis C
An Integrated Care Model for Improving Hepatitis C Virus Patient Outcomes
This is a prospective randomized controlled trial comparing two different clinic models for patients with hepatitis C. These patients commonly have mental health problems that are barriers to receiving HCV treatment.
- Trial name
- HCV (NCT00722423)
- Testing
- Integrated care model, Usual Care Model
- Where
- 3 sites in United States
- Volunteers
- 364 people
- Sponsor
- US Department of Veterans Affairs
Hepatitis C, Chronic
Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs
We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection…
- Trial name
- NCT04943588
- Testing
- HCV RNA (PCR), HCV Antibody test (Point of care), AST/ALT and platelets measurement
- Where
- Pakistan
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Alcoholism, Alcohol Abuse
Health Behavior Feedback Study for Veterans With Hepatitis C
The purpose of this study was to explore whether a brief (3 session) intervention would impact health behavior of veterans with hepatitis C.
- Conditions
- Alcoholism, Alcohol Abuse, Hepatitis C, Liver Disease
- Trial name
- NCT00229580
- Testing
- 3 session brief intervention with health behavior feedback, treatment as usual
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Washington
Hepatitis C
Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy Subjects
The purpose of this study is to assess the effect of BMS-791325 on the pharmacokinetics of the CYP3A4 Probe Midazolam.
- Trial name
- NCT00996879
- Testing
- Midazolam, BMS-791325
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HCV, Hepatitis C Infection
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.
- Conditions
- HCV, Hepatitis C Infection, Genotype 4
- Trial name
- NCT02247401
- Testing
- 2 DAA, RBV
- Volunteers
- 160 people
- Sponsor
- AbbVie
Hepatitis C, Chronic
Real World Study: Genotype 1 Chronic Hepatitis C Virus Treatment and Evaluation of Real World SVR and PRO
This is a Phase IV, open-label, multi-center study to evaluate the real world sustained virological response rate, subject adherence, and subject reported outcomes during and after treatment of non-cirrhotic genotype 1 chronic…
- Trial name
- NCT02461745
- Testing
- ombitasvir, paritaprevir/r, dasabuvir + ribavirin, ombitasvir, paritaprevir/r, dasabuvir
- Where
- 4 sites in United States
- Volunteers
- 200 people
- Sponsor
- Kaiser Permanente
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.